CION Ameerpet
Finishing treatment is a milestone, not the end of care. This guide explains how lymphoma monitoring after treatment works — the visit schedule, when surveillance scans are (and are not) needed, the warning signs to watch for, and how CION checks for late effects.
Once active treatment ends, you move into the follow-up phase — a planned programme of reviews designed to do three things: catch any return of the lymphoma early, watch for late effects of the treatment you had, and support your recovery. It is a reassuring, structured continuation of your care, not a sign that anything is wrong. If you have reached this stage in complete remission, follow-up is what keeps that remission under a careful, expert eye.
A key thing to understand is that modern lymphoma monitoring after treatment is deliberately symptom-led rather than scan-heavy. The strongest evidence, reflected in both NCCN and ESMO guidance, is that most relapses are picked up because of a new symptom, an examination finding, or a change in blood tests — not because of a routine scan in someone who feels well. So good follow-up leans on a careful conversation and examination at each visit, with imaging used purposefully when there is a reason.
This page walks through the schedule, the role of surveillance scans lymphoma protocols now assign, the warning signs to report, and the long-term late-effect monitoring that matters for survivors. For the wider picture, see the Lymphoma hub, our Lymphoma Treatment in Hyderabad page, and the best lymphoma hospital in Hyderabad overview.
Both NCCN and ESMO follow-up guidelines now recommend against routine surveillance imaging (such as scheduled CT or PET-CT) in patients who are in complete remission and free of symptoms. The evidence shows these "just in case" scans rarely find relapse before symptoms or blood tests do, while adding radiation exposure, cost and anxiety. Follow-up is therefore built around history, examination and blood tests — with imaging reserved for when there is a genuine clinical reason. (Source: NCCN Clinical Practice Guidelines and ESMO Clinical Practice Guidelines for Hodgkin and non-Hodgkin lymphoma follow-up.)
Follow-up is most intensive in the first two years — when relapse risk is highest — and then eases as time passes. This is a general guide; your own schedule is individualised to your subtype, stage and response.
| Time After Treatment | Typical Review Interval | What Each Visit Involves |
|---|---|---|
| Year 1–2 | Every 3–6 months | History, physical examination, blood tests; imaging only if indicated |
| Year 3–5 | Every 6–12 months | History, examination, blood tests; late-effect screening begins in earnest |
| Beyond year 5 | Yearly | Long-term survivorship checks — heart, lung, thyroid, bone, second-cancer screening |
Intervals vary by individual and by lymphoma subtype; this table is a general guide aligned with NCCN and ESMO follow-up recommendations. Some indolent subtypes are monitored on their own long-term rhythm — see long-term outlook with indolent lymphoma.
Good surveillance is as much about what we don't do — unnecessary scans — as what we do. Here is what shapes follow-up at CION.
We follow NCCN and ESMO standards, which means a careful symptom-and-examination approach with imaging used only when clinically justified — protecting you from needless radiation and "scanxiety" while staying alert to real warning signs.
Your schedule reflects your subtype, stage, how you responded, and your prognostic profile. Tools such as the prognostic index (IPI / FLIPI) help us judge how intensively to monitor and when the interval can safely lengthen.
Your lymphoma specialists, imaging, pathology and supportive-care services sit under one roof, so a concern raised at a visit can be investigated quickly and reviewed by a tumour board.
Follow-up is not only about relapse. We screen for late effects and support fatigue, emotional wellbeing and return to normal life — the focus of our survivorship care.
We're never more than 30 minutes away. Same panel of specialists at every centre. Same tumour board reviews. Same NCCN protocols. Pick the closest one and call directly — or let us pick for you.
CION Ameerpet
CION Kukatpally
CION L.B. Nagar
CION Tolichowki
CION Masab Tank
CION Banjara Hills
CION Kompally
CION Balanagar
CION Siddipet
CION Sangareddy
Not sure which centre fits best? Tell us where you are — we'll suggest the closest one with the right specialists.
Help me pick the right centreTravelling for treatment? We may have a centre right where you are.
Don't see your city? Call 18002028726 — we'll find your nearest CION partner centre.
Trained at AIIMS, Tata Memorial, and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them — together.
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationShare your name and number — we'll call you back within 30 minutes to schedule your consultation.
Whether you have just finished treatment, want your follow-up plan reviewed, or noticed a symptom that is worrying you, CION's lymphoma team is here to help.
Because follow-up is symptom-led, you are an active part of your own surveillance. Knowing which changes to report — and reporting them promptly rather than waiting for the next appointment — is one of the most powerful ways to detect a return of lymphoma early. Contact your team if you notice:
Most of these turn out to have an ordinary explanation — but they are exactly the "B symptoms" that can signal lymphoma activity, so they should always be checked rather than ignored. Speak to a CION lymphoma specialist if any of these appear during your follow-up.
If a symptom, examination finding or blood-test change raises concern, follow-up shifts into a clear, stepwise investigation. This is when imaging earns its place — used purposefully rather than routinely.
A PET-CT or CT of the area of concern is used to look for active disease. Unlike routine surveillance scanning, this is a directed test with a specific question to answer, which makes its result far more meaningful. The imaging is arranged and interpreted by the CION team as part of coordinated care.
Imaging can suggest a relapse, but it cannot prove one. A biopsy of the suspicious node or site is needed to confirm that lymphoma is present and to re-check its features — because a subtype can occasionally change or transform over time, which alters the plan. CION performs biopsy and bone-marrow assessment directly.
Confirmed findings are taken to a multidisciplinary tumour board, where the next steps are decided together. For a fuller picture of how likely a return is and what it means, see lymphoma recurrence — risk & monitoring and what relapse means & how likely it is. Where disease is more persistent, our page on living with advanced or hard-to-treat lymphoma explains the options.
Outcomes after lymphoma treatment are often very good, which is exactly why long-term follow-up matters. Published series report roughly 80–90% long-term survival for Hodgkin lymphoma and, for the common non-Hodgkin subtype diffuse large B-cell lymphoma, roughly 60–70%, with figures rising when treatment is curative. These are population averages — your own outlook depends on your subtype, stage, prognostic score and response, so figures vary by individual. (Source: figures consistent with published outcome series referenced in NCCN and ESMO lymphoma guidelines.)
Because so many people live for decades after lymphoma treatment, a core part of follow-up looks beyond relapse to the possible long-term effects of the therapy you received. What is monitored depends on your specific treatment:
Some chemotherapy classes and chest radiation can affect the heart and lungs over time. Follow-up may include periodic checks of heart and lung function, with lifestyle advice to protect them.
Radiation near the neck can affect the thyroid, and some treatments influence bone density and fertility. These are checked and managed proactively, and fertility questions are discussed openly.
A small increased risk of second cancers can follow certain treatments — for example, earlier breast screening is advised for women who had chest radiation at a younger age. Appropriate screening is built into the long-term plan.
Fatigue, low mood and anxiety about scans are common and real. Follow-up makes space to address them — an essential part of life after lymphoma treatment. Note that stem-cell transplant and CAR-T cell therapy, when needed, are coordinated through accredited partner facilities.
A second opinion on your surveillance plan is especially worthwhile if:
CION offers a dedicated, free written second-opinion service. You deserve a plan built around healing, not billing — with transparent costs explained up front. Request your free second opinion or call 18002028726.
Get a free written second opinion from CION's lymphoma tumour board on your follow-up schedule, symptom concerns, and late-effect monitoring.
These aren't paid endorsements or written reviews. These are video testimonials from real patients and families — recorded on their own phones, in their own words. Pick any one. Watch it. Then decide.
Read all 800+ reviews on Google
Start Your Story. Book Free Consultation.Follow-up is most intensive in the first two years, because that is when the risk of relapse is highest. A common pattern, in line with NCCN and ESMO follow-up guidance, is a clinic review every 3–6 months for the first 2 years, then every 6–12 months up to year 5, and yearly after that. The exact schedule depends on your lymphoma subtype, the stage, how you responded to treatment, and any ongoing symptoms. Each visit includes a history, physical examination and blood tests, with imaging only when it is clinically justified. At CION your lymphoma team tailors the interval to your individual risk, and the plan is reviewed at every appointment.
For most people, routine surveillance scans lymphoma protocols have shifted away from scanning at fixed intervals when there are no symptoms. Both NCCN and ESMO advise against routine surveillance CT or PET-CT in patients who are in complete remission and symptom-free, because scans rarely detect relapse before symptoms or blood tests do, and they add radiation exposure and anxiety. Instead, imaging is used when a new symptom, an abnormal examination finding, or a blood-test change raises concern. Some higher-risk subtypes may be monitored more closely. Your doctor will explain exactly when a scan is warranted rather than scanning "just in case".
Lymphoma monitoring after treatment is built around three simple pillars: a careful history (asking about symptoms such as new lumps, fevers, drenching night sweats, unexplained weight loss or fatigue), a physical examination (checking lymph-node areas, the spleen and liver), and blood tests (full blood count and other markers). Imaging is added selectively when something needs clarifying. Follow-up also screens for late effects of treatment — heart, lung, thyroid and second-cancer risk — and supports your recovery. Read more about life after lymphoma treatment and what long-term wellbeing looks like.
You do not have to wait for your next scheduled visit. Contact your team promptly if you notice a new or enlarging lump, unexplained fevers, drenching night sweats, unintentional weight loss, persistent fatigue, itching, new pain, or breathlessness. These are the same "B symptoms" that can signal lymphoma activity, and picking them up early is exactly why symptom-based follow-up works well. Most such symptoms turn out to have an ordinary cause, but they should always be checked. If you are worried, book a review with a CION specialist or call 1800 202 8726 — you will not be a nuisance for asking.
If your history, examination or blood tests suggest the lymphoma may have returned, the next step is targeted imaging — usually a PET-CT or CT of the relevant area. Imaging alone is not enough to confirm relapse: a biopsy of the suspicious node or site is needed to prove that lymphoma is present and to re-check its features, because a subtype can sometimes change over time. This is why we investigate rather than assume. For a fuller explanation of what a return of disease means, see lymphoma recurrence — risk & monitoring and what relapse means & how likely it is.
It feels reassuring to be scanned, but the evidence shows that routine scans in a symptom-free person who is in remission rarely change outcomes — most relapses are found because of a symptom or a blood-test change first, not because of a scheduled scan. Guidelines from NCCN and ESMO therefore recommend against reflex surveillance imaging and favour a careful, symptom-driven approach that also limits radiation exposure. CION follows this evidence-led standard: we scan when there is a reason to, and we explain that reason to you. This measured approach protects you from unnecessary tests while keeping a close eye on genuine warning signs.
Because many people live for decades after treatment, follow-up looks beyond relapse to the possible long-term effects of chemotherapy, immunotherapy and radiation. Depending on what you received, this can include monitoring heart and lung function, thyroid activity, bone health, fertility questions, and screening for second cancers — for example, breast screening after chest radiation at a younger age. Emotional wellbeing, fatigue and "scanxiety" are addressed too. This survivorship focus is a core part of good follow-up. Learn more on our life after lymphoma — survivorship page, and see what remission means in lymphoma.
Browse our complete guide to lymphoma — symptoms, diagnosis, Hodgkin and non-Hodgkin subtypes, treatment, genetics, prognosis, survivorship and cost. Tap any topic to read more.